Alvotech
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lisa Graver
- Full Time Employees
- 1,012
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Saemundargata 15-19 Luxembourg Iceland 102
- IPO Date
- Jun 16, 2022
- CIK
- 0001898416
- Website
- alvotech.com
- Similar Companies
- Business
- Alvotech Ltd (ALVO) is an Iceland-based biotechnology company that develops, manufactures and commercializes biosimilar and novel biologic drugs targeting autoimmune, eye and other diseases. The company offers a portfolio of products including AVT02, a biosimilar to Humira (adalimumab) for treating rheumatoid arthritis, psoriasis and other inflammatory conditions; AVT04, a biosimilar to Stelara (ustekinumab) for psoriasis and Crohn's disease; AVT06, a biosimilar to Eylea (aflibercept) for retinal diseases; and AVT23, a biosimilar candidate to Keytruda (pembrolizumab) for oncology indications, along with pipeline candidates in ophthalmology and other therapeutic areas. Alvotech operates primarily in the United States, Europe and select emerging markets through strategic partnerships with companies such as Teva Pharmaceutical Industries, STADA Arzneimittel, Biocon Biologics and Intas Pharmaceuticals for commercialization and distribution. Founded in 2013 and headquartered in Reykjavik, Iceland, the company focuses on high-quality biosimilars produced using its proprietary continuous manufacturing platform to improve yield, reduce costs and accelerate market entry. In recent developments, Alvotech secured U.S. FDA approval for AVT04 (Selarsdi) in October 2024 and launched it commercially through its partner Teva in early 2025; expanded its partnership with Biocon for AVT02 commercialization in Europe; completed a significant funding round in 2024 to support pipeline advancement; and announced positive Phase 3 topline results for AVT06 in mid-2025, positioning it for regulatory submission.
Transactions of Managers and Closely Associated Persons
Alvotech further strengthens liquidity by securing term loan facility of $75 million
Transactions of Managers and Closely Associated Persons
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Transactions of Managers and Closely Associated Persons
Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions
Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
Main Results of 2026 Annual and Extraordinary General Meeting
Alvotech to present at upcoming investor conferences in June
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
Alvotech (ALVO) Presents at Bank of America Global Healthcare Conference 2026 Transcript